Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations

v3.26.3
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Operating expenses:        
Research and development $ 6,710,035 $ 9,797,418 $ 23,202,834 $ 24,011,452
General and administrative 1,905,389 1,953,014 6,323,886 5,383,737
Total operating expenses 8,615,424 11,750,432 29,526,720 29,395,189
Loss from operations (8,615,424) (11,750,432) (29,526,720) (29,395,189)
Other income 453,556 170,306 1,390,823 350,130
Net loss $ (8,161,868) $ (11,580,126) $ (28,135,897) $ (29,045,059)
Net loss per share, basic (in dollars per share) $ (0.89) $ (5.93) $ (3.39) $ (19.58)
Net loss per share, diluted (in dollars per share) $ (0.89) $ (5.93) $ (3.39) $ (19.58)
Weighted-average outstanding Common Shares, basic (in shares) 9,143,340 1,953,352 8,303,704 1,483,150
Weighted-average outstanding Common Shares, diluted (in shares) 9,143,340 1,953,352 8,303,704 1,483,150